Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07385547 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
A Phase 1 study of Type II Diabetes Mellitus, sponsored by Sun Pharmaceutical Industries Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT07385547 is a Phase 1 study of Type II Diabetes Mellitus that is actively recruiting participants, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 40 participants, below the 168-participant average among 7 other Type II Diabetes Mellitus trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT07385547, a Phase 1 study of Type II Diabetes Mellitus, is actively recruiting participants, sponsored by Sun Pharmaceutical Industries Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe renal impairment without dialysis, and severe renal impairment with dialysis. Each participant will receive a single subcutaneous dose of GL0034. Blood samples will be collected for PK analysis. Secondary objectives include assessing safety and tolerability. The study will help determine whether renal impairment affects GL0034 exposure and inform dosing recommendations for patients with compromised renal function.
Conditions Studied
Interventions
- DRUG GL0034
Study Locations (3)
Florida
- Syneos Miami - Miami
- Panax Clinical Research - Miami Lakes
- Orlando Clinical Research Center (OCRC) - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-02-25 |
| Est. Completion | 2026-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07385547
The ClinicalTrials.gov registry entry for NCT07385547 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 7 other Type II Diabetes Mellitus trials with a reported enrollment target (76% lower). The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type II Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which GL0034 is the first listed.
NCT07385547 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07385547 about?
NCT07385547 is a clinical study titled "Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency". This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal ...
What is the current status of trial NCT07385547?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-02-25. Estimated completion is 2026-09-27.
What conditions does trial NCT07385547 study?
This clinical trial studies the following conditions: Type II Diabetes Mellitus.
What interventions are being tested in trial NCT07385547?
The interventions under investigation include: GL0034 (DRUG).
Who is sponsoring clinical trial NCT07385547?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07385547 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type II Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
RECRUITING · Phase 2
-
The GRoceries Aimed at Increasing Nutrition Study
RECRUITING · NA
-
Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes
COMPLETED · NA
-
Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients
COMPLETED · Phase 2
-
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
COMPLETED · Phase 3
-
The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.